PODDPODD
US • —
$152.25
P/E
35.45
PEG
—
FCF Yield
—
Rev Growth YoY
+31.9% YoY
Gross Margin
71.0%
Health Score
7/10
D/E Ratio
0.63
Confidence
MEDIUM
Business Snapshot
Insulet Corporation designs, develops, and manufactures the Omnipod system, a tubeless insulin pump for people with diabetes. This replaces traditional insulin delivery methods with a wearable, waterproof pod that is controlled wirelessly. The company operates in the large and growing diabetes management market, competing against traditional insulin pump manufacturers like Medtronic and Tandem Diabetes, holding a strong challenger position with its unique tubeless design. Market capitalisation data is unavailable, but the business generates substantial revenue as indicated by a 31.9% year-over-year revenue growth rate. A defining characteristic is its first-mover advantage and intellectual property moat surrounding the Omnipod platform's tubeless, disposable form factor.
Financial Health
Gross margin stands at a strong 71.0%, indicating significant pricing power and efficient production for its disposable pods. Net margin is 10.4%, showing the company is converting a reasonable portion of revenue into net income...
Risk Assessment
- EARNINGS QUALITY — Net income fell 21.1% year-over-year despite a 31.9% revenue increase, indicating that growth is not translating into higher earnings.
- VALUATION — P/E of 35.45x commands a 61% premium to the sector average of 22x.
- FCF / CASH BURN — Free cash flow is unavailable or negative, making a DCF calculation impossible and raising a question about cash generation.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....
Gross margin stands at a strong 71.0%, indicating significant pricing power and efficient production for its disposable pods. Net margin is 10.4%, showing the company is converting a reasonable portion of revenue into net income. The balance sheet is healthy, with a moderate Debt/Equity ratio of 0.63x and a strong Current Ratio of 2.81x, providing ample liquidity to meet short-term obligations. Free cash flow data is not reported, preventing a full assessment of cash generation versus earnings quality. Overall, the company operates with low financial risk and a strong ability to reinvest in growth, though a lack of cash flow data is a limitation.
- EARNINGS QUALITY — Net income fell 21.1% year-over-year despite a 31.9% revenue increase, indicating that growth is not translating into higher earnings. - VALUATION — P/E of 35.45x commands a 61% premium to the sector average of 22x. - FCF / CASH BURN — Free cash flow is unavailable or negative, making a DCF calculation impossible and raising a question about cash generation. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives